Business Context and Reporting Period
Company: StemCells, Inc. (Note: Request metadata listed "Microbot Medical Inc.", but the filing text identifies the registrant as StemCells, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2003
Business Overview: The Company is engaged in the research and development of human therapeutic products, specifically focusing on stem cell technology for neural and liver diseases. It has not commercialized any products and relies on external financing, grants, and collaborative arrangements to fund operations.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2003 | Six Months Ended June 30, 2002 |
|---|---|---|
| Total Revenue | $119,250 | $236,628 |
| Net Loss | $(5,122,152) | $(5,868,054) |
| Net Loss Applicable to Common Stockholders | $(6,657,287) | $(6,672,881) |
| Net Loss Per Share (Basic & Diluted) | $(0.23) | $(0.27) |
| Cash and Cash Equivalents (End of Period) | $6,534,355 | $7,782,229 |
| Net Cash Used in Operating Activities | $(4,314,770) | $(5,607,316) |
| Total Assets | $13,636,621 | $11,328,822 |
| Total Liabilities | $5,091,240 | $4,881,565 |
Debt and Obligations: The Company has capital lease obligations of approximately $2.2 million (outstanding principal) related to a pilot manufacturing facility in Rhode Island. There is also a mandatory redemption obligation of $2,000,000 for remaining 3% Cumulative Convertible Preferred Stock due December 4, 2003.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 50% year-over-year (from $236,628 to $119,250). This was primarily due to the conclusion of a Small Business Innovation Research (SBIR) grant in 2002 and a decrease in licensing revenue.
- Expense Reduction: Operating expenses decreased by approximately 15% year-over-year. Research and Development (R&D) expenses dropped from $3.65 million to $3.08 million, and General and Administrative (G&A) expenses dropped from $2.39 million to $2.07 million. These reductions were driven by a cost-cutting program initiated in late 2002 and a lease amendment reducing rent expenses at the California facility.
- Deemed Dividend: A significant non-cash charge of approximately $1.49 million was recorded as a "deemed dividend" in the six months ended June 30, 2003 (compared to $0.64 million in 2002). This resulted from a reduction in the conversion price of preferred stock held by The Riverview Group, LLC, allowing for a conversion that relieved the Company of a cash redemption obligation.
- Liquidity Improvement: Despite operating losses, cash balances increased from $4.24 million at year-end 2002 to $6.53 million at June 30, 2003, primarily due to a $6.5 million equity financing transaction in May 2003.
Guidance, Outlook, and Risks
- Capital Resources: Management expects current capital resources to be sufficient to fund operations into 2004. However, the Company has incurred significant losses since inception and expects to continue incurring losses for the foreseeable future.
- Going Concern: The filing includes a "going concern" warning. The Company has very limited liquidity and must obtain significant additional capital to sustain product development, clinical testing, and regulatory pursuits. Failure to secure funding could force the Company to delay or eliminate programs.
- Facility Obligations: The Company faces significant ongoing lease obligations for facilities in Rhode Island (approximately $1 million net cost for 2003). While subleasing portions of the facility, the Company is actively seeking to assign or sell these interests to terminate obligations.
- Nasdaq Compliance: The Company previously faced delisting risks due to stock price falling below $1.00 but regained compliance with Nasdaq listing requirements in May 2003.
- Scientific Progress: Preclinical studies for human central nervous system stem cells (hCNS-SCs) in models of Batten Disease and Spinal Cord Injury showed proof of principle, encouraging further development.
Investor Verification Checklist
- Runway Validation: Verify if the $6.5 million raised in May 2003 is sufficient to fund operations through 2004 given the high burn rate and ongoing facility costs.
- Preferred Stock Redemption: Confirm the status of the remaining $2,000,000 preferred stock redemption due December 4, 2003, and the Company's plan to settle this obligation.
- Facility Disposal: Monitor progress on subleasing or selling the Rhode Island facilities to eliminate the net $1 million annual loss associated with these leases.
- Revenue Sustainability: Assess the sustainability of revenue streams, as the Company currently has no commercial product sales and relies heavily on grants and one-time licensing fees.
- Dilution Risk: Review the impact of the equity line of credit with Sativum Investments and the warrant issued to Riverview on future share count and dilution.